Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer

Cancer Gene Therapy

Volumn 19, Issue 6, 2012, Pages 374-381

  Hanna, N ^a   Ohana, P ^b   Konikoff, F M ^c   Leichtmann, G ^c   Hubert, A ^d   Appelbaum, L ^d   Kopelman, Y ^e   Czerniak, A ^f   Hochberg, A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Institute of Life Sciences   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e HILLEL YAFFE MEDICAL CENTER   (Israel)

^f SHEBA MEDICAL CENTER   (Israel)

Author keywords

BC 819; diphtheria toxin A; H19 gene; pancreatic cancer

Indexed keywords

BC 819; GEMCITABINE; PLASMID DNA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD DISEASE; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPIC ECHOGRAPHY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GINGIVA BLEEDING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INJECTION SITE PAIN; INOPERABLE CANCER; INTERNATIONAL NORMALIZED RATIO; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PAIN; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SYNCOPE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VASCULAR DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DIPHTHERIA TOXIN; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PLASMIDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROMOTER REGIONS, GENETIC; RNA, UNTRANSLATED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84861197235     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.10     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. El-Kamar FG, Grossbard ML, Kozuch PS. Metastatic pancreatic, cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003; 8: 18-34. (Pubitemid 36232353)
3. Gunji N, Oda T, Todoroki T, Kanazawa N, Kawamoto T, Yuzawa K et al. Pancreatic carcinoma: correlation between E-cadherin and alpha-catenin expression status and liver metastasis. Cancer 1998; 82: 1649-1656. (Pubitemid 28208913)
4. American Joint Committee on Cancer Classification. Cancer Staging Manual. edn. American Joint Committee on Cancer Classification ISBN: 0-387-95270-5.
5. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19: 4202-4208. (Pubitemid 33081637)
6. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. (Pubitemid 27251144)
7. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
8. Hazard L. The role of radiation therapy in pancreas cancer. Gastrointest Cancer Res 2009; 3: 20-28.
9. Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Gallula J et al. Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer. J Oncol 2010; 2010: 178174.
10. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med 2009; 7: 69.
11. Sidi A, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 overexpressing superficial bladder cancer refractory to bacillus calmette guerin. J Urol 2008; 180: 2379-2383.
12. Erdmann VA, Barciszewska MZ, Szymanski M, Hochberg A, de Groot N, Barciszewski J. The non-coding RNAs as riboregulators. Nucleic Acids Res 2001; 29: 189-193. (Pubitemid 32054443)
13. Ariel I, Lustig O, Schneider T, Pizov G, Sappir M, De-Groot N et al. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995; 45: 335-338.
14. Ariel I, Ayesh S, Perlman EJ, Pizov G, Tanos V, Schneider T et al. The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol 1997; 50: 34-44.
15. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N et al. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 1998; 51: 21-25. (Pubitemid 28157352)
16. Rachmilewitz J, Goshen R, Ariel I, Schneider T, de Groot N, Hochberg A. Parental imprinting of the human H19 gene. FEBS Lett 1992; 309: 25-28.
17. Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W et al. Possible physiological role of H19 RNA. Mol Carcinog 2002; 35: 63-74.
18. Matouk I, deGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A et al. The H19 noncoding RNA is essential for human tumor growth. PloS ONE 2007; 2: e845.
19. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-239. (Pubitemid 47101660)
20. Matouk I, Mazan S, Mizrahi A, Ohana P, Abu-lail R, Fellig Y et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 2010; 1803: 443-451.
21. Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990; 19: 793-810.
22. Gress F, Michael H, Gelrud D, Patel P, Gottlieb K, Singh F et al. EUS-guided fineneedle aspiration of the pancreas: evaluation of pancreatitis as a complication. Gastrointest Endosc 2002; 56: 864-867. (Pubitemid 36236717)
23. Fernandez-Esparrach G, Gines A, Garcia P, Pellisé M, Solé M, Cortés P et al. Incidence and clinical significance of hyperamylasemia afer EUS FNA of pancreatic lesions: a prospective and controlled study. Endoscopy 2007; 39: 720-724. (Pubitemid 47299940)
24. Mizrahi A, Czerniak A, Ohana P, Amiur S, Gallula J, Matouk I et al. Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. J Med Case Reports 2010; 4: 228-231.